The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol

Stefano Aliberti1,2*, Luigi Ruffo Codecasa3, Andrea Gori4, Giovanni Sotgiu5, Maura Spotti1,2, Antonio Di Biagio6, Andrea Calcagno7, Stefano Nardini8, Baroukh Maurice Assael1,2, Enrico Tortoli9, Giorgio Besozzi10, Maurizio Ferrarese3, Alberto Matteelli11, Enrico Girardi12, Saverio De Lorenzo13, Manuela Seia14, Andrea Gramenegna1,2, Bruno Del Prato15, Leonardo Terranova16, Martina Oriano1,2, Nicola Sverzellati17, Mehdi Mirsaied18, James D. Chalmers19*, Charles S. Haworth20, Michael R. Loebinger21, Timothy Aksamit22, Kevin Winthrop23, Felix C. Ringshausen24, Giuliana Previdi25, Francesco Blasi1,2 and on behalf of the IRENE Network

From 2nd World Bronchiectasis Conference
Milan, Italy. 06-08 July 2017

Abstract

Background: A substantial increase in pulmonary and extra-pulmonary diseases due to non-tuberculous mycobacteria (NTM) has been documented worldwide, especially among subjects suffering from chronic respiratory diseases and immunocompromised patients. Many questions remain regarding the epidemiology of pulmonary disease due to NTM (NTM-PD) mainly because reporting of NTM-PD to health authorities is not mandated in several countries, including Italy. This manuscript describes the protocol of the first Italian registry of adult patients with respiratory infections caused by NTM (IRENE).

Methods: IRENE is an observational, multicenter, prospective, cohort study enrolling consecutive adult patients with either a NTM respiratory isolate or those with NTM-PD. A total of 41 centers, including mainly pulmonary and infectious disease departments, joined the registry so far. Adult patients with all of the following are included in the registry: 1) at least one positive culture for any NTM species from any respiratory sample; 2) at least one positive culture for NTM isolated in the year prior the enrolment and/or prescribed NTM treatment in the year prior the enrolment; 3) given consent to inclusion in the study. No exclusion criteria are applied to the study. Patients are managed according to standard operating procedures implemented in each IRENE clinical center. An online case report form has been developed to collect patients’ demographics, comorbidities, microbiological, laboratory, functional, radiological, clinical, treatment and outcome data at baseline and on an annual basis. An IRENE biobank has also been developed within the network and linked to the clinical data of the registry.

Conclusions: IRENE has been developed to inform the clinical and scientific community on the current management of adult patients with NTM respiratory infections in Italy and acts as a national network to increase the disease’s awareness.

* Correspondence: stefano.aliberti@unimi.it; j.chalmers@dundee.ac.uk
1Department of Pathophysiology and Transplantation, University of Milan, Via Francesco Sforza 35, 20122 Milan, Italy
19Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Pulmonary disease due to non-tuberculous mycobacteria (NTM) has always been a tangible clinical entity [1]. An increase in NTM pulmonary and extra-pulmonary morbidity and mortality has been documented in Italy and worldwide, especially among patients suffering from chronic respiratory diseases, including bronchiectasis, chronic obstructive pulmonary disease (COPD), or cystic fibrosis (CF), as well as among HIV-positive and other immunocompromised patients [2–11]. Several determinants of the increasing epidemiological trend have been identified: the aging of the population with high prevalence of chronic and debilitating diseases; an intensified use of immunosuppressive therapies; a broader use of chest CT; a high diagnostic yield of microbiological conventional and molecular techniques; an increasing environmental exposure to NTM; an increase use of antibiotics which can favor the occurrence of niches for NTM; declining rates of M. tuberculosis infection; and a potential impact of person-to-person transmission as recently suggested among CF patients [12, 13].

Many questions remain regarding the epidemiology of pulmonary disease due to NTM (NTM-PD), which is characterized by symptomatic, progressive inflammatory lung damage and defined in 2007 in the American Thoracic Society (ATS) / Infectious Diseases Society of America (IDSA) guidelines [14, 15]. These epidemiological and clinical uncertainties on NTM-PD cause significant confusion for clinicians in daily clinical practice when asked to diagnose NTM-PD. The clinical relevance of specific NTM respiratory isolates significantly varies from patient to patient, and the interplay between exposure- and host-related factors is poorly understood [15]. NTM-PD shows a wide spectrum of clinical manifestations and frequently is diagnosed in the context of concomitant respiratory diseases (e.g., bronchiectasis, COPD, or CF) [3]. Geographical diversity is another important factor in the epidemiology of NTM. A large inter- and intra-country heterogeneity in distribution of NTM species has been recently shown [16, 17]. Finally, an Italian experience described NTM-PD risk factors whose qualitative and quantitative ascertainment could help clinicians to discriminate between colonization and disease [18].

Reporting of NTM-PD to health authorities is not mandated in several countries and the current estimates have been obtained from sentinel surveillance or laboratory-based studies, retrospective cohort studies, or audits of administrative databases. Only few European countries (i.e., UK, Greece, Germany, and the Netherlands) have provided epidemiological data, showing an incidence rate of NTM isolation ranging from 2.9 to 7.0 per 100,000 population and a NTM-PD prevalence of 0.7–1.7 per 100,000 population, with a marked increase as aging occurs [19–21]. Until now no data have been published on the epidemiology of respiratory NTM infections in Italy.

On this basis, robust national longitudinal data are needed. This manuscript describes the protocol of the first Italian registry of adult patients with respiratory infections caused by NTM.

Methodology of the Irene registry

Study design

The Italian registry of pulmonary NTM (IRENE) is an observational, multicenter, prospective, cohort study enrolling consecutive adult patients with either a NTM respiratory isolate or those with NTM-PD. The coordinating center is located at the Pulmonary Department of the Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico (hereby referred to as Policlinico Hospital), Milan, Italy, where the central approval from the Ethical Committee (EC) for this study was obtained on March 6th, 2017, and the first patient was enrolled on April 21st, 2017. A total of 42 centers, including mainly pulmonary and infectious disease (ID) departments, joined the registry so far, see Fig. 1. All the centers are also required to obtain local EC approval before entering the registry. All patients must provide written informed consent to participate in the registry. The study is sponsored by the Policlinico Hospital in Milan. The study website is located at www.registroirene.it and the study has been registered at clinicaltrial.gov (NCT03339063).

Study subjects

Adult (≥18 years) patients with all of the following are included in the registry: 1) at least one positive culture for any NTM species from any respiratory sample; 2) at least one positive culture for NTM isolated in the year prior the enrolment and/or prescribed NTM treatment in the year prior the enrolment; 3) given consent to inclusion in the study. No exclusion criteria are applied to the study in order to increase the generalizability of the results. The inclusion criteria of the registry clearly identify a population of patients characterized by a recent/ongoing history of either a NTM infection or NTM-PD (Table 1). Patients who received NTM treatment in the year prior to enrolment but did not have a positive culture for NTM isolated in this period of time could be included in the study if still they
had at least one positive culture for any NTM species from any respiratory sample in their history. The IRENE Executive Committee decided not to limit the enrolment to patients with NTM-PD, but to follow up also patients with a recent NTM infection not fulfilling the 2007 ATS/IDSA criteria for NTM-PD [15].

Patients included in the registry are mainly recruited among pulmonary and ID out- and in-patient services. Adult CF, lung transplant, and tuberculosis clinics represent other recruitment centers. A heterogeneous population of patients with NTM infection/NTM-PD sharing different clinical phenotypes is expected to be enrolled in the registry. IRENE has a special focus on four patients’ categories: 1) immunocompetent/bronchiectatic, 2) HIV-positive, 3) CF and 4) lung transplanted patients. 500 patients are expected to be enrolled in the registry by the end of 2020. The registry has been developed to accept an unlimited number of patients and no deadlines have been decided.

Data collection, definitions and quality control

Patients are managed according to standard operating procedures (SOPs) implemented in each IRENE clinical center without any interference from the study team. A baseline case report form (CRF) is collected at patient’s enrolment including demographics, comorbidities, microbiological, laboratory, functional, radiological, clinical, and treatment data. Then, study investigators will enter follow-up data on an annual basis. Furthermore, a “start treatment” and a “stop treatment” CRFs are also collected. The database incorporates automated logic checks put in place to avoid the collection of out-of-range values. Once the case is entered into the registry, two members of the study team (SA and MS) manually verified its consistency and data queries will be solved with the local study investigator. In case of unresolved queries or incomplete cases, they will be rejected to have high quality data. To assure the high quality of the data, random audit will also be conducted at study sites.

IRENE biobank

An IRENE biobank has also been developed within the network and linked to the clinical data of the registry. IRENE sites can collect samples, including blood, serum, plasma, respiratory specimens (e.g., sputum, induced
sputum, tracheal aspirate, or bronchoalveolar lavage), urine, and NTM isolates at the first visit and during follow-up on a voluntary basis. The same SOPs for biological collection, processing, and storage (first locally and then centralized at the Policlinico Hospital in Milan for analysis) will be adopted by all IRENE sites.

The registry governance and the IRENE network
The registry is held securely at the Health Informatics Centre (HIC) of the Policlinico Hospital in Milan, Italy, and de-identified data will be accessible to the principal investigator and to all IRENE investigators on request to the Executive Committee. Analysis of the entire IRENE database will be allowed after the submission of a research question, along with a specific study protocol, to the IRENE Scientific Committee. IRENE investigators will have unrestricted access to their own data. The database will be run in accordance with the principles of Good Clinical Practice. Study results will be disseminated in the form of annual reports, conference abstracts, and peer reviewed publications. The IRENE network will follow the International Committee of Medical Journal Editors recommendations regarding authorship.

IRENE is the official Italian network within the EMBARC European NTM registry [22]. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) registry is a prospective, pan-European observational study of adult patients with bronchiectasis, including those with NTM. Patients enrolled in the EMBARC registry undergo a comprehensive baseline assessment and are followed-up annually for up to 5 years with the goal of providing high-quality longitudinal data on outcomes, treatment patterns and quality of life [22]. All Italian patients included in the EMBARC European NTM registry will be enrolled through IRENE and IRENE data will be incorporated into the EMBARC European NTM registry.

IRENE also promotes multi-disciplinary education and patient-professional collaboration in the field of NTM through its relationship with national scientific societies. There is a lack of a platform for communication between patients with NTM infection/NTM-PD and physicians in Italy and some patients within the IRENE network already expressed their will to develop a patient advisory group.

The NTM Consilium
Inspired by recent successful initiatives supporting physicians in their decisions to manage difficult-to-treat patients with respiratory infection, such as the ERS/WHO TB Consilium, a free-cost, Italian, internet-based consultation system will be developed within the IRENE website, the IRENE NTM Consilium [23]. IRENE investigators will have access to this platform to seek advice from national experts on the clinical management of complicated NTM cases and will receive a suggestion in less than 3 working days. A call for experts will precede the launch of this initiative.

Discussion
Several registries and merging platforms for international cohorts have been developed on different respiratory diseases, including community-acquired pneumonia (the CAPO database), bronchiectasis (EMBARC and FRIENDS), or primary ciliary dyskinesia over the past decades [24, 25]. Registries are invaluable tools which can help investigators to better understand the natural history, the epidemiology, and the management of a specific disease [26]. Results from the registries may inform both the clinical community on real-life data and the scientific experts on tracks for future interventional studies.

The largest registry including NTM patients running so far is the United States Bronchiectasis Research Registry (BRR) which is a database sponsored by the COPD Foundation and which has enrolled 1826 non-CF bronchiectasis patients at 13 sites in the USA until now [27]. The first report from the BRR has been recently published showing 63% of the population with a history of NTM disease or NTM isolation [27]. Important differences between bronchiectasis patients with and without NTM were identified by the authors. Although extremely informative, this registry has been mainly developed as a bronchiectasis registry with some specific data on NTM-PD. IRENE may integrate BRR data because it includes > 40 sites where NTM patients are cared by both pulmonary and ID physicians to fully explore the disease heterogeneity.

IRENE has been developed: 1) to strengthen the network of pulmonologists, infectious diseases physicians, and other healthcare providers caring for adult patients with NTM; 2) to prospectively collect demographics, clinical, microbiological, radiological, functional, and therapy variables, as well as long-term outcomes; 3) to longitudinally collect clinical, biological and mycobacteriological samples for future translational research on NTM; 4) to assess the heterogeneity in the clinical manifestation of the disease and its current management; 5) to release national SOPs and guidelines based on precise epidemiological data; 4) to increase NTM disease awareness at national and international levels. The IRENE network is composed by pulmonologists, ID physicians, clinical microbiologists, tuberculosis, CF and lung transplant specialists, radiologists, public health experts, translational researchers, an international advisory board of NTM experts, as well as patients suffering from NTM infections. IRENE has been designed to be open for collaboration with other national and international registries in the field of NTM. The IRENE data fields and protocol are aligned with the European NTM registry to ensure data can be shared between IRENE and the European NTM Registry for collaborative analysis [22].
Conclusions
NTM-PD is considered a neglected and rare disease and there are limited observational and experimental data on epidemiology of this condition and its management. A substantial improvement in the understanding of NTM infection and NTM-PD is needed to develop new therapies and improve patients’ outcomes. IRENE has been developed to inform the clinical and scientific community on the current management of adult patients with NTM respiratory infections in Italy and acts as a national network to increase the disease’s awareness.

Abbreviations
ATS: American Thoracic Society; BRR: Bronchiectasis Research Registry; CAPO: Community-Acquired Pneumonia Organization; CF: Cystic Fibrosis; COPD: Chronic Obstructive Pulmonary Disease; CRF: Case Report Form; CT: Computed Tomography; EC: Ethical Committee; EMBARC: European Multicentre Bronchiectasis Audit and Research Collaboration; FRIENDS: Facilitating Research Into Existing National Databases; HIC: Health Informatics Centre; HIV: Human Immunodeficiency Virus; ID: Infectious Disease; IRENE: Infectious Diseases Society of America; IRCCS: Istituto di Ricovero e Cura a Carattere Scientifico; IRENE: The Italian Registry of Pulmonary Non-tuberculous mycobacteria; IRS: Italian Respiratory Society; NTM: Non-Tuberculous Mycobacteria; NTM-PD: Pulmonary disease due to NTM; PCO: Primary Ciliary Dyskinesia; SOPs: Standard Operating Procedures; TB: Tuberculosis; UK: United Kingdom

Acknowledgements
The IRENE Executive Committee wants to acknowledge the support of Dr. Giuliana Fusetti, Dr. Manuela Martorana, Dr. Gennaro Colella, Avv. Giuseppina Verga, Dr. Gerardina Carbone, Dr. Isabella Damilano, Dr. Fabrizio Nava, Dr. Lisa Pancini, Dr. Ana Pasat and Dr. Nicolò Vanoni from the Policlinico Hospital in Milan, and of the Invisiblefarm company. The IRENE network also recognizes the support of the Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Milano, the University of Milan, the Italian Ministry of Health, the Italian Respiratory Society (Società Italiana di Pneumologia - SIP/IRS), the Italian Society of Cystic Fibrosis (SIFC), STOP-TB Italia and the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC).

Funding
The sponsor of IRENE is Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy, which received so far an unrestricted grant by Insmed Incorporated. Publication costs of this article will be funded by Novamedia and Italian Respiratory Society (IRS).

Availability of data and materials
The IRENE dataset will be available from the corresponding author on reasonable request to IRENE Executive Committee. IRENE has been registered at clinicaltrial.gov (NCT03330963).

About this supplement
This article has been published as part of Multidisciplinary Respiratory Medicine Volume 13 Supplement 1, 2018: Bronchiectasis: still an orphan disease?. The full contents of the supplement are available online at https://mrmjournal.biomedcentral.com/articles/supplements/volume-13-supplement-1.

Authors’ contributions
All authors participated in the drafting and revising of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The approval from the Ethical Committee (EC) of the coordinating center (Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy) has been obtained on March 6th, 2017 (8BI_2017ibs). All the IRENE centers are required to obtain local EC approval before entering the registry. All enrolled patients (up to 20th July 2018) gave their written informed consent to participate in the registry.

Consent for publication
Not applicable.

Competing interests
Prof. Alberti received grants from Insmed and Fisher and Paykel, and consultancy/lecture fees from Bayer Healthcare, Grifols, Zambon, Chiesi, Horizon Pharma and Insmed. Prof. Chalmers reports grants from Bayer Healthcare, Glaxosmithkline, Boehringer Ingelheim, AstraZeneca, Insmed, Pfizer and Grifols, and personal fees from Napp and Chiesi. Dr. Cocodea received consultancy fees from Insmed. Dr. Loeinger has received consultancy and lecture fees from Insmed. Prof. Haworth received unrestricted educational grants, speaker fees and consultancy fees from Insmed. Prof. Gorl received grants/research supports from Abbvie, Astellas, BMS, Boeringher, Gilead, Janssen, MSD, Novartis, Pfizer, Roche and VIV; honoraria or consultation fees from BMS, Gilead, Janssen, MSD, Novartis and VIV; travel grant supports from BMS, Gilead, Janssen, and VIV; and he participated in a company sponsored speaker’s bureau for Gilead. Dr. Winthrop received grants and consulting from Insmed. All the other authors declare that they have no competing interests. Prof. Francesco Blasi is Editor-in-Chief of Multidisciplinary Respiratory Medicine, whereas Profs. Stefano Alberti, Giovanni Scrigli, Stefano Nardini are Associate Editor of Multidisciplinary Respiratory Medicine. In addition, Prof. Stefano Alberti and Prof. James Chalmers are Guest Editors of the Supplement on Bronchiectasis.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pathophysiology and Transplantation, University of Milan, Via Francesco Sforza 35, 20122 Milan, Italy. Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy. Regional TB Reference Centre, Istituto Villa Marelli, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. "Clinic of Infectious Diseases, San Gerardo” Hospital-ASST Monza, University Milano-Bicocca, Milan, Italy. Clinical Epidemiology and Medical Statistics Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. 'Clinica Malattie Infettive, Policlinico Ospedale S. Martino, Genoa, Italy. Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy. Ospedale Civile, Pulmonary and TB Unit, Vittorio Veneto, Italy. Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. StopTB Italia, Milano, Italy. WHO Collaborating Centre for TB/HIV co-infection and TB Elimination, Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. Clinical Epidemiology Unit, National Institute for Infectious Disease ‘L Spallanzani, Rome, Italy. 8E. Morelli Hospital ASST, Reference Center for MDR-TB and HIV-TB, Sondolo, Italy. 9Medical Genetics Laboratory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. Unit of Interventional Pulmonology, High Speciality “A. Cardarelli” Hospital, Naples, Italy. "Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milano, Italy. Science Radiologiche, Dipartimento di Medicina e Chirurgia, Università di Parma, Parma, Italy. 12Miami Veterans Administration Medical Center, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami School of Medicine, Miami, FL, USA. Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. 15Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK. Host Defence Clinic, Royal Brompton Hospital, London, UK. Mayo Clinic College of Medicine, Rochester, MN, USA. 16Oregon Health and Science University, Portland, OR, USA. “Dept of Respiratory Medicine, Member of the German Centre for Lung Research, Hannover Medical School, Hannover, Germany. "Aziende Socio Sanitarie Territoriale Melegnano e della Martesana, Vizzolo Predabissi, Milan, Italy.

Published: 9 August 2018

References
1. Pierismoni C, Scarpa C. Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis. 2008;8:323–34.
2. Rindi L, Ganzelli C. Increase in non-tuberculous mycobacterium isolated from humans in Tuscany, Italy, from 2004 to 2014. BMC Infect Dis. 2016;16:44.
3. Bonati G, Pesci A, Marruchella A, Lapadula G, Gori A, Aliberti S. Nontuberculous Mycobacteria in Nonscystic Fibrosis Bronchiectasis. Biomed Res Int. 2015;2015:197950.

4. Favero P, Stainer A, Bonati G, Zuccgetti SC, Simonetta E, Lapadula G, et al. Characterizing nontuberculous mycobacteria infection in bronchiectasis. Int J Mol Sci. 2016;17(11).

5. Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013; 34:87–94.

6. Prevots DR, Marnas TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36:13–34.

7. Van der Werf MJ, Ködmön C, Katalinić-Janković V, Kummik T, Soini H, Richter E, et al. Inventory study of nontuberculous mycobacteria in the European Union. BMC Infect Dis. 2014;14:62.

8. Ringhausen FC, Apel RM, Bange FC, de Roux A, Pletz MW, Rademacher J, et al. Burden and trends of hospitalisations associated with pulmonary nontuberculous mycobacterial infections in Germany, 2005–2011. BMC Infect Dis. 2013;13:231.

9. Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing trends of nontuberculous mycobacteria infection in England, Wales and Northern Ireland, 1995–2006. BMC Public Health. 2010;10:612.

10. Biondi G, Sotgiu G, Dore S, Molicotti P, Ruggeri M, Aliberti S, et al. Beyond pulmonary nontuberculous mycobacteria disease: do extra-pulmonary forms represent an emerging clinical and public health threat? ERJ Open Res. 2017;3(3).

11. Mirsaeidi M, Machado RF, Garcia JS, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLoS One. 2014;9(e91879).

12. Brode SK, Daley CL, Marnas TK. The epidemiologic relationship between tuberculosis and nontuberculous mycobacterial disease: a systematic review. UTLD. 2014;18:370–7.

13. Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016;354:751–7.

14. Diel R, Jacob J, Lampenius N, Loebinger M, Nienhaus A, Rabe KF, et al. Burden of nontuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. 2017;49(4).

15. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.

16. Hoeﬂoot W, van Ingen J, Andrejak C, Angelyk K, Bauriaud R, Berner P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2015;46:1304–13.

17. Mirsaeidi M, Vu A, Leitman P, Sharifi A, Wisliceny S, Leitman A, et al. A patient-based analysis of the geographic distribution of Mycobacterium avium complex, Mycobacterium abscessus, and Mycobacterium kansasii infections in the United States. Chest. 2017;151:947–50.

18. Mencarini J, Cesici C, Simonetti MT, Truppa C, Camiciottoli G, Frilli ML, et al. Non-tuberculous mycobacteria: epidemiological pattern in a reference laboratory and risk factors associated with pulmonary disease. Epidemiol Infect. 2017;145:515–22.

19. Henry MT, Imandar L, O’Riordan D, Schweiger M, Watson JP. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J. 2004;23:741–6.

20. Gerogiani I, Papala M, Kostikas K, Petinaki E, Gourgoulianis KI. Epidemiology and clinical significance of mycobacterial respiratory infections in Central Greece. Int J Tuberc Lung Dis. 2008;12:807–12.

21. van Ingen J, Bendien SA, de Lange WC, Hoeﬂoot W, Dekhuijzen PN, Boere MJ, et al. Clinical relevance of nontuberculous mycobacteria isolated in the Nijmegen-Arnhem region, the Netherlands. Thorax. 2009;64:502–6.

22. Chalmers JD, Aliberti S, Pavanico E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European bronchiectasis registry: protocol for an international observational study. ERJ Open Res. 2016;2(1).

23. O’Ambrosio L, Tadolini M, Cerisi R, Duarte R, Sotgiu G, Aliberti S, et al. Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. Int J Infect Dis. 2015;32:156–60.

24. Aliberti S, Peyrani P, Filardi G, Mirsaeidi M, Amir A, Basi F, et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest. 2011;140:482–8.

25. Goutaki M, Maurer E, Halbeisen FS, Amirav I, Barbato A, Behan L, et al. The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results. Eur Respir J. 2017;49(1).

26. McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zuccgetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016;71:110–8.

27. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels ML, et al. Adult Patients with Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest. 2017;151:982–92.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions